Innate Pharma to Participate in Upcoming Investor Conferences – QNT Press Release


Regulatory News:

Innate Pharma SA (PARIS:IPHNASDAQ:IPHA) (“Innate” or the “Company“) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences:

  • HC Wainwright Annual Global Life Sciences Conference

    Event Date: May 23-25, 2022

  • Citi’s European Healthcare Conference

    Event Date: June 16, 2022

About Innate Pharma:

Innate Pharma SA is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center